Core Viewpoint - The announcement highlights the upcoming presentation of the first human Phase 1 clinical study design for the novel targeted antibody-drug conjugate (ADC) MesoC2 (HBM9033/PF-08052666) at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, in collaboration with Pfizer [1] Group 1 - MesoC2 was initially developed by the company's wholly-owned subsidiary, Nona Bioscience, utilizing its proprietary Harbour Mice platform and integrated ADC platform, and was licensed to Pfizer through a global agreement in December 2023 [1] - The ADC is currently undergoing a Phase 1 open-label study targeting various advanced solid tumor patients [1] - Pfizer will present clinical research information at the ASCO annual meeting, including a study assessing the safety and tolerability of MesoC2 in advanced solid tumor patients, with the abstract number TPS3163 and poster number 475a [1] Group 2 - MesoC2 has demonstrated significant anti-tumor efficacy in in vitro tests and xenograft models, showing acceptable safety characteristics in cynomolgus monkeys [2] - The Phase 1 trial (NCT06466187) will be conducted with dose escalation, dose optimization, and cohort expansion, evaluating up to 365 patients for MesoC2's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy based on RECIST v1.1 criteria [2]
和铂医药-B(02142)：MESOC2首次人体1期临床研究设计将于2025年ASCO年会发表